Alzheimer’s disease is one of the most common causes of dementia, affecting millions of people worldwide. Scientists continue to explore new ways to understand the biological processes behind memory loss and identify potential approaches for protecting brain function.

One compound attracting growing scientific interest is cannabidiol (CBD), a non-intoxicating compound found in the cannabis plant. Previous laboratory studies have suggested that CBD may influence processes related to neuroinflammation, synaptic function and brain health. However, exactly how these effects occur has remained unclear.

A recent study from researchers at Shenzhen University in China, published in the peer-reviewed journal Molecular Psychiatry, has identified a potential molecular mechanism that may help explain some of CBD’s effects in an Alzheimer’s disease mouse model.


CBD and Brain Function in Mice

The researchers used a genetically modified mouse model of Alzheimer’s disease and administered CBD over a 45-day period.

Compared with untreated mice, the CBD-treated animals showed improvements in certain measures of cognitive performance and anxiety-related behaviour. The researchers also observed changes in dendritic spines and synaptic structures, which are important for communication between brain cells and play a key role in learning and memory.

These findings suggest that CBD may influence several biological processes associated with brain function in this animal model.

But the most interesting part of the research was the mechanism behind these observations.


A New Link to the TrkB Signaling Pathway

The study found that CBD can activate TrkB (tropomyosin receptor kinase B), a receptor involved in neuronal survival, development and synaptic plasticity.

TrkB is commonly activated by brain-derived neurotrophic factor (BDNF), an important protein involved in maintaining healthy neurons and supporting learning and memory.

Interestingly, the researchers found that the CBD-related activation of TrkB did not appear to depend on increased BDNF levels. This suggests that CBD may influence TrkB through a different molecular route.

The team then identified FRS2, a signaling adaptor protein, as an important molecular target involved in this process.


FRS2: A Potential Molecular “Glue”

Using a combination of biochemical experiments and molecular modeling, the researchers found evidence that CBD can interact with FRS2 and influence the interface between FRS2 and TrkB.

The researchers describe this mechanism as being similar to a “molecular glue”: rather than simply blocking a protein, CBD may help stabilize the interaction between two proteins and strengthen downstream TrkB signaling.

When FRS2 levels were reduced in the experimental models, several of the effects associated with CBD were also weakened. This further supports the importance of FRS2 in the observed mechanism.


What Does This Mean for Alzheimer’s Disease?

The findings provide an interesting new direction for Alzheimer’s disease research. Rather than simply showing that CBD produces certain effects in an animal model, the study offers a possible explanation for how CBD may influence neuronal signaling.

However, it is important to keep the findings in perspective.

This research was conducted primarily in cells and animal models. It does not establish that CBD can treat, prevent or reverse Alzheimer’s disease in humans. Human studies are still needed to determine whether this molecular mechanism translates into meaningful clinical benefits.

For now, the discovery of the FRS2–TrkB pathway represents an intriguing area for further research and may help scientists explore new approaches to understanding neurodegenerative diseases.